Active GLP-1 (7-36) amide Chemiluminescence ELISA

Glucagon-like peptide-1 (GLP-1) is an extensively well-characterized incretin hormone which regulates both insulin and glucagon secretion. GLP-1 is a highly sought after therapeutic target due to its beneficial effects on glucose homeostasis, particularly through regulation of beta cell mass, function, and viability. GLP-1 is produced in intestinal L-cells in response to food and is well conserved across species. GLP-1 is derived from the cleavage of proglucagon to generate a 1-37 amino acid peptide. Fasting reduces circulating levels of GLP-1. GLP-1 has many physiological effects on the body. Diabetes and obesity scientists have been using two main  GLP-1 research approaches: DPP-4 inhibition and GLP-1 analogs. DPP-4 can inactivate GLP-1 to its forms of GLP-1 (9-36 amide) and GLP-1 (9-37). By inhibiting DPP-4, scientists hope that GLP-1 can continue to influence insulin secretion and restore balance to energy homeostasis. The goal of developing GLP-1 analogs is to engineer a better GLP-1 molecule that has a longer half-life, thus providing longer influences over insulin secretion.